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Abstract
South Africa led the world with guidelines on bedaquiline (BDQ) use as a single drug substi-
tution to manage rifampin resistant tuberculosis regimen toxicity. We examined reasons for
giving BDQ in a retrospective cohort: >75% of patients were switched to BDQ for toxicity
(ototoxicity or renal dysfunction) rather than drug resistance.
Background
Patients with rifampin-resistant tuberculosis (RR-TB) often have baseline resistance to addi-
tional drugs in the second-line TB regimens [1] and as many as 80% develop side effects [2]
(such as hearing loss from injectables (SLI)), leading to global demand for new agents. In June
2015, South Africa became one of the first countries to use newly-available bedaquiline (BDQ)
for single drug substitution to manage second-line drug toxicity [3], as long as the patient was
not failing current therapy. Single drug substitution is only reasonable if a patient has a strong
regimen background and the new drug is being introduced for toxicity reasons. If a patient is
failing therapy then at least two new effective drugs should be introduced to avoid resistance
acquisition. Whether South Africa’s BDQ implementation strategy would balance the need for
a less toxic drug to prevent further patient disability with international calls for strict TB drug
stewardship to mitigate risk of BDQ introduction into weak regimens is not known [4].
BDQ’s long half-life (6 months) may make it particularly vulnerable to resistance acquisi-
tion [5], especially in settings with high treatment loss to follow-up. Emergence of BDQ resis-
tance is well documented [4]. In one study, BDQ resistance-associated variants were found in
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6.3% of BDQ-naïve multidrug-resistant (MDR) TB isolates, suggesting a role of prior TB drug
exposure [6] and possibly transmission of drug-resistant strains. Nonetheless, in August 2018,
supported by a meta-analysis [7] and observational studies [8], the WHO recommended
including BDQ as a group A drug in long course MDR-TB regimens [9]. With this change,
evaluation of programmatic use of BDQ is urgently needed.
We retrospectively examined the indications for BDQ introduction to patients’ regimens
and available resistance test results at the time of BDQ initiation among a cohort of South Afri-
can patients being treated for RR-TB.
Methods
We conducted a retrospective cohort study of all RR-TB patients at Brewelskloof Hospital,
Worcester, South Africa who initiated treatment from December 2015 through June 2017. Eli-
gible patients had evidence of RR-TB by genotypic or phenotypic drug susceptibility testing
(DST) and were�18 years old. Phenotypic DST was performed until December 2016 and
genotypic DST was used from January 2017 onwards. Brewelskloof Hospital is the regional
referral inpatient TB facility and RR-TB care is practiced according to South African National
Treatment Program tuberculosis guidelines [10]
During the study period, an 18–24 month RR-TB regimen was administered with SLI for
the initial 6–8 months. Additional drugs included in the regimen were high dose isoniazid,
pyrazinamide, ethambutol, ethionamide, terizidone and moxifloxacin (levofloxacin was substi-
tuted where BDQ was added). South African national guideline-approved indications for the
switch to BDQ included: additional drug resistance (fluoroquinolone (FQN), SLI, or both
inhA promoter and katG gene mutations), moderate to severe toxicity due to second line
agents (e.g., hearing loss or renal dysfunction), or history/candidate for pneumonectomy/
lobectomy [10]. In September 2015, the Western Cape Department of Health (DOH)
expanded drug access and BDQ applications were reviewed by the provincial or national clini-
cal advisory committee prior to medication provision. If FQN/SLI resistance was detected,
patients received an individualized regimen based on DST testing potentially containing the
additional drugs, PAS, linezolid or clofazimine. BDQ was dosed according to the South Afri-
can national guideline: 400mg daily for 2 weeks, then 200mg daily on Monday, Wednesday
and Friday for 22 weeks. Continuation of BDQ beyond 6 months required clinical advisory
committee approval.
Data were abstracted from TB registers, laboratory registers, and EDRweb.net, along with
detailed review of patient hospital records, including: medication administration records,
audiometry, provincial/national committee BDQ applications, and clinical notes. In addition
to the guideline-approved indications for switch to BDQ described above [10], two additional
committee approved indications were noted in chart review. In one case, the patient’s age was
thought to put them at increased risk for SLI intolerance, and in two cases clinical RR-TB regi-
men failure (persistent culture positivity without additional drug resistance on DST) were
approved as indications for switching to a BDQ-containing regimen (the regimens were fur-
ther individualized in the clinical failure cases). Study data were collected and maintained in
REDCap (https://projectredcap.org/).
We compared baseline characteristics between patients treated with and without BDQ
using Pearson chi-squared, Fisher’s exact test, and Student t-tests where appropriate. Among
those treated with BDQ, we then analyzed the indications for switching, available DST, and
additional chemotherapeutic agents added at the time of BDQ initiation. Analysis was com-
pleted using SAS version 9.4.
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Results
Of 173 RR-TB patients who initiated treatment, one patient (0.6%) who had prior treatment
failure was initiated on an individualized BDQ-containing regimen and 75 (43.4%) were
switched to a regimen with BDQ (Fig 1). Of all included patients, 62.4% were HIV co-infected
(Table 1). Use of BDQ increased steadily during the study period. In the first 7 months of this
cohort, 18.7% (14/75) of RR-TB patients received BDQ, which increased to 50.9% (28/55) dur-
ing the following 6 months and finally to 79.1% (34/43) in the final 6 months. All patients were
treated with at least five drugs. Compared to those who did not receive BDQ, patients who
received BDQ were older (median 41.6 years vs 37.3, p = 0.0145, Table 1). There were no other
Fig 1. Flow diagram of rifampin resistant tuberculosis patients at brewelskloof hospital.
https://doi.org/10.1371/journal.pone.0223308.g001






173 97 (56.1) 76 (43.9)
Male (%) 91/173 (52.6) 52 (53.6) 39 (51.3) 0.76
Age, years (mean, SD) 39.1 (11.4) 37.3 (10.2) 41.6 (12.5) 0.01
Extrapulmonary disease (%) 39/173 (22.5) 18 (18.6) 21 (27.6) 0.16
At least 1 Prior TB Episode (%) 130/172 (75.6) 75 (78.1) 55 (72.4) 0.38
BMI (mean, SD) 19.01 (4.5) 18.85 (3.9) 19.18 (5.1) 0.65
HIV positive (%): 108/173 (62.4) 58 (59.8) 50 (65.8) 0.42
Abbreviations: SD, standard deviation; TB, tuberculosis; BMI, body mass index; HIV, human immunodeficiency virus.
https://doi.org/10.1371/journal.pone.0223308.t001
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significant differences in baseline demographic characteristics between the two groups
(Table 1).
The reason for BDQ introduction was additional drug resistance in 21.1% (16/76) of cases
and intolerance of second line therapy in 76.3% of cases (58/76, Table 2), of which>70% was
attributed to hearing loss. DST to SLIs and FQNs was completed at the time of switch to BDQ
in 79.0% of patients (60/76, Table 2). Among those with DST available, 21.7% had SLI/FQN
resistance detected (13/60, Table 2); additional drugs were added along with BDQ in all cases
(Table 2). However, among the 16 patients for whom SLIs and FQN testing was unknown, the
switch to BDQ was approved as a single drug substitution in 15/16 (93.8%, Table 2).
Discussion
In our retrospective cohort of patients hospitalized with RR-TB, BDQ use increased steadily
during the 19-month study period. FQN and SLI susceptibility results were available in >75%
of individuals switched to BDQ. All patients found to have FQN or SLI resistance had addi-
tional drugs added to strengthen their regimen at the time of BDQ switch. However, a small
group of patients with unknown FQN/SLI susceptibility felt to be responding to treatment also
received committee-approval for single drug substitution. Those who received BDQ were
switched overwhelmingly for hearing loss from SLIs rather than additional drug resistance.
Our findings of high rates of hearing loss with SLI treatment are consistent with other studies
[11] and further support removing SLIs from first line MDR-TB therapy.
Table 2. Indications for the use of bedaquiline, second line drug susceptibility test results when bedaquiline was
started, and the resulting changes in regimen among patients who received bedaquiline (n = 76).
Total (%) N (%)
Additional Drug Resistance (%): n = 16 (21.1)
� Both InhA and KatG 3/76 (3.9)
� Pre-XDR 11/76 (14.5)
� XDR 2/76 (2.6)
Intolerance of SL drugs (%): n = 58 (76.3)
�Hearing loss 41/76 (53.9)
� Renal Dysfunction 10/76 (13.2)
� Both renal and hearing 5/76 (6.6)
� Neuropathy 1/76 (1.3)
� Age 1/76 (1.3)
History/candidate for pneumonectomy/lobectomy (%): n = 0 (0.0)
Clinical Treatment Failure (%): n = 2 (2.6)
FQN/SLI testing:
�Available 60/76 (79.0)
� Not Available 16/76 (21.0)
FQN/SLI resistance unknown: 16/76 (21.0)
� Additional drugs added 1/16 (6.3)
FQN/SLI resistance detected: 13/60 (21.7)
� Additional drugs added 13/13 (100.0)
Abbreviations: additional drug resistance, resistance to drugs beyond rifampin and isoniazid; pre XDR, pre
extensively drug resistant (resistant to either a second line injectable or fluoroquinolone); XDR, extensively drug
resistant (resistant to both second line injectables and fluoroquinolones; SL, second line; FQN, fluoroquinolone; SLI
second line injectable
https://doi.org/10.1371/journal.pone.0223308.t002
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In September 2015, the Western Cape Provincial DOH expanded BDQ access. Providers
could gain approval via a standardized application to give BDQ to patients who had adverse
reactions to the standard regimen. In our cohort,<20% of RR-TB patients initiated on treat-
ment between December 2015 and June 2016 were switched to BDQ compared to almost 80%
of patients a year later. Early during the roll out at Brewelskloof Hospital, there was an episode
of severe QTc prolongation attributed to BDQ, which may have led providers to be more cau-
tious in prescribing the newer drug and instead continuing with the prior practice of SLI dose
adjustment for toxicity. Our study lacked qualitative insight into clinician prescribing prac-
tices, but the trend indicates that with experience and lack of additional negative events, pro-
viders did readily change to the new medication option within a year of its introduction.
The South African programmatic Clinical Advisory Review Committee process was created
to ensure that all patients with known FQN/SLI resistance were switched to an optimized
BDQ regimen that includes additional effective drugs. Our data show this method of steward-
ship to be relatively effective. Globally, optimal use of and access to companion medications
have been universal obstacles as countries roll out BDQ [3]. In settings like South Africa where
routine second line DST is limited to FQN, SLI, and ethionamide (via mutations in the inhA
promoter region on line probe assay) and with more than half of global MDR-TB cases esti-
mated to be resistant to pyrazinamide [12], the strength of the BDQ backbone regimen is diffi-
cult to guarantee. A significant limitation of our study was the inability to assess whether BDQ
resistance emerged. Under the previous WHO MDR-TB regimen recommendations, South
Africa opted to allow for BDQ use as a single substitution for adverse reactions if the patient
did not appear to be failing their regimen. Patients with a single substitution within a strong
backbone regimen should not be at increased risk of acquiring resistance, but future work
should monitor these patients to ensure this assumption is correct. Our work highlights that
despite a well-developed national health laboratory system, there remain patients for whom
SLI/FQN susceptibility is unknown, in addition to the drugs (pyrazinamide, ethambutol, teri-
zidone) that are not tested. While lack of second line DST may have been due to early culture
conversion in those patients, suggesting good clinical response to therapy, ongoing surveil-
lance is needed to confirm that switching to BDQ remains safe and effective without leading to
additional emergence of resistance.
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